R&D News | pharmaphorum

News

Apnimed IPO raises $192m, as three other biotechs set terms

Sleep apnoea drug developer Apnimed has completed its IPO, raising $192m, while Braveheart, Attovia, and Vogenx reveal their terms.

News

Woman with vitiligo crosses her arms in front of her chest

Pfizer cues up vitiligo filing for Litfulo after phase 3 win

Pfizer's JAK inhibitor Litfulo hits the mark in vitiligo, setting up filings, as Incyte claims EU approval for Opzelura in atopic dermatitis.

News

Sanofi drops two more programmes in R&D clear-out

Shortly after terminating one late-stage R&D programme, Sanofi confirmed in its second-quarter update that two others are being scrapped.

News

J&J takes $2.58bn option to buy in vivo CAR-T firm Sail

Johnson & Johnson has bid for a slice of the in vivo CAR-T category, signing an alliance with Sail Bio that could evolve into a $2.58bn takeover.

News

Simple blood test could aid in global TB fight

A blood test for tuberculosis that can distinguish between dormant and active infections has shown promise in a clinical trial.

News

A man drunken on vodka lies in the grass

Altimmune alcohol use disorder drug hits the mark in phase 2

Altimmune's pemvidutide has been shown to reduce drinking in people with alcohol use disorder, adding to the evidence for GLP-1 drugs in this setting.

Apnimed IPO raises $192m, as three other biotechs set terms

Pfizer cues up vitiligo filing for Litfulo after phase 3 win

Sanofi drops two more programmes in R&D clear-out

J&J takes $2.58bn option to buy in vivo CAR-T firm Sail

Simple blood test could aid in global TB fight

Altimmune alcohol use disorder drug hits the mark in phase 2

Datroway joins Trodelvy for frontline TNBC in the EU

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks